Cargando…

The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1

The stromal microenvironment controls response to injury and inflammation, and is also an important determinant of cancer cell behavior. However, our understanding of its modulation by miRNA (miR) and their respective targets is still sparse. Here, we identified the miR-25-93-106b cluster and two ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Cioffi, Michele, Trabulo, Sara M, Vallespinos, Mireia, Raj, Deepak, Kheir, Tony Bou, Lin, Meng-Lay, Begum, Julfa, Baker, Ann-Marie, Amgheib, Ala, Saif, Jaimy, Perez, Manuel, Soriano, Joaquim, Desco, Manuel, Gomez-Gaviro, Maria Victoria, Cusso, Lorena, Megias, Diego, Aicher, Alexandra, Heeschen, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400610/
https://www.ncbi.nlm.nih.gov/pubmed/28423491
http://dx.doi.org/10.18632/oncotarget.15450
Descripción
Sumario:The stromal microenvironment controls response to injury and inflammation, and is also an important determinant of cancer cell behavior. However, our understanding of its modulation by miRNA (miR) and their respective targets is still sparse. Here, we identified the miR-25-93-106b cluster and two new target genes as critical drivers for metastasis and immune evasion of cancer cells. Using miR-25-93-106b knockout mice or antagomiRs, we demonstrated regulation of the production of the chemoattractant CXCL12 controlling bone marrow metastasis. Moreover, we identified the immune checkpoint PD-L1 (CD274) as a novel miR-93/106b target playing a central role in diminishing tumor immunity. Eventually, upregulation of miR-93 and miR-106b via miR-mimics or treatment with an epigenetic reader domain (BET) inhibitor resulted in diminished expression of CXCL12 and PD-L1. These data suggest a potential new therapeutic rationale for use of BET inhibitors for dual targeting of cancers with strong immunosuppressive and metastatic phenotypes.